FDA vaccine head will step down in April after string of controversial decisions

Dr. Peter Marks, the FDA's vaccine chief, is reportedly stepping down in April, which could introduce uncertainty into the regulatory landscape for vaccines. His departure follows several high-profile and debated decisions, suggesting potential shifts in the FDA's approach to vaccine approvals and emergency use authorizations. Investors should monitor the appointment of his successor and any immediate policy changes, as this could impact pharmaceutical companies with vaccine pipelines and public health initiatives.